Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials ...

Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...

Amid a cautious outlook, Biogen has presented new data at the Alzheimer’s Association International Conference (AAIC) 2025, demonstrating that investigational Leqembi 360 mg subcutaneous maintenance ...

Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above ...

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...

Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...

Of the companies that reported their results last week, 18 beat analysts’ earnings forecasts, while 3 missed. On the revenue ...

A week ago, Biogen Inc. ( NASDAQ:BIIB ) came out with a strong set of quarterly numbers that could potentially lead ...

US biotech major Biogen (Nasdaq: BIIB) reported a 7% rise in its second quarter revenue Friday, with sales of $2.45 billion.